OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE)

University Medical Center Groningen (UMCG)

Status and phase: Not yet enrolling; Phase 4

Conditions: Thyroid Carcinoma; Ovarian Carcinoma; Endometrium Carcinoma; Breast Carcinoma; Renal Cell Carcinoma

Treatments: Drug: Pazopanib; Drug: Lenvatinib; Drug: Olaparib; Drug: Palbociclib; Drug: Sunitinib

Study type: Interventional

Funder types: Other

Identifiers

NCT05949424

16800

Details and patient eligibility

About

The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same. The trial population consists of 30 patients aged 65 years or older, who are starting treatment with one of these anti cancer tablet treatments: pazopanib, olaparib, lenvatinib, sunitinib or palbociclib. The control group (half of the participants) will be treated with the standard-of-care, the interventional group will start with the lowest dose of the anti cancer tablets as described in the drug label. The dose will be increased every two weeks in case of good tolerability. Results of this pilot study will be used to inform the design of the larger randomised phase 2 trial.

Full description

Information about the benefits and side effects of treatments for cancer is mainly derived from studies with younger patients. It is known that elderly patients experience more side effects from treatments, which can lead to a worse quality of life. The study hypothesis is that a lower starting dose of anticancer tablet treatments can lead to better treatment tolerability in older patients, while the benefits of treatment can be the same.

The trial population consists of 30 patients aged 65 years or older, who are starting treatment with one of these anti cancer tablet treatments: pazopanib, olaparib, lenvatinib, sunitinib or palbociclib. This is a randomized study with 1:1 randomisation, stratified by type of anti-cancer treatment.

The control group (half of the participants) will be treated with the standard-of-care, that means with the recommended starting dose of the anti cancer tablets as described in the drug label. The dose can be adjusted (lowered) if this is necessary, for example because of side effects, based on the judgment of the treating physician. The interventional group (half of the participants) will start with the lowest dose of the anti cancer tablets as described in the drug label. The dose will be increased every two weeks in case of good tolerability. Results of this pilot study will be used to inform the design of the larger randomised phase 2 trial, for example the primary endpoint, the amount of investigations and the size of the study population.

Study visits are planned every 2 weeks for a total study duration of 12 weeks, the time point for analysis of the primary endpoint. Blood samples for PK analysis are collected every 2 weeks. A baseline blood sample will be collected for pharmacogenomic analysis.

Enrollment: 30 estimated patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients ≥ 65 years of age.
• Indication for starting treatment with pazopanib (for renal cell carcinoma), olaparib (for ovarian carcinoma), lenvatinib (as monotherapy for thyroid carcinoma, or in combination with pembrolizumab for renal cell carcinoma or endometrium carcinoma), sunitinib (for renal cell carcinoma) or palbociclib (for breast carcinoma).
• No contra-indications for starting treatment at the recommended starting dose as per SmPC.
• All patients must provide written informed consent prior to enrolment.

Exclusion criteria

• Planned starting dose lower than the recommended starting dose as per SmPC

For Pazopanib:

• Use of a strong CYP3A4-inhibitor or PgP-inhibitor
• Creatinine clearance <30ml/min
• Moderate or severe hepatic impairment (bilirubin >1.5x ULN)

For Olaparib:

• Use of a moderate or strong CYP3A4-inhibitor
• Creatinine clearance <50 ml/min
• Severe hepatic impairment (Child-Pugh 10-15)

For Lenvatinib:

• Creatinine clearance <30ml/min
• Severe hepatic impairment (Child-Pugh score 10-15)

For Sunitinib:

• Use of a strong CYP3A4-inhibitor
• Use of a strong CYP3A4-inducer

For Palbociclib:

• Use of a strong CYP3A4-inhibitor
• Severe hepatic impairment (Child-Pugh score 10-15)
• Other findings at interview or physical examination that hamper compliance to the study protocol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

30 participants in 2 patient groups

Control group

Active Comparator group

Description:

Standard SmPC dosing with dose adjustments for toxicity as per SmPC

Treatment:

Drug: Palbociclib

Drug: Sunitinib

Drug: Pazopanib

Drug: Palbociclib

Drug: Lenvatinib

Drug: Olaparib

Drug: Pazopanib

Drug: Lenvatinib

Drug: Olaparib

Drug: Sunitinib

Intervention group

Experimental group

Description:

Lower starting dose with dose-escalation inversely following the dosing steps from the SmPC every 2 weeks in case of good tolerability

Treatment:

Drug: Palbociclib

Drug: Sunitinib

Drug: Pazopanib

Drug: Palbociclib

Drug: Lenvatinib

Drug: Olaparib

Drug: Pazopanib

Drug: Lenvatinib

Drug: Olaparib

Drug: Sunitinib